About Us

AeonClad Coatings is a surface modification company with expertise in customizing coatings using plasma processing.

AeonClad was formed in 2007 to develop an advanced coating technology platform to address the need to control the interaction of novel materials with their local environments through technology licensed from the University of Texas, Arlington. AeonClad, as a specialty coatings company, was founded on the pioneering research of Dr. Richard Timmons and his team. AeonClad is funded and managed by life sciences venture firm, Emergent Technologies, Inc.

In 2009, AeonClad established AeonClad Biomedical, LLC as a subsidiary to focus on drug delivery and medical device markets. AeonClad Coatings continues to focus primarily on industrial applications, including the semiconductor, bottom paint (marine), flame retardant, and chromatography industries, among others.

Management

Chief Scientist
Richard Timmons, Ph.D.
		Dr. Timmons is a University of Texas at Arlington (UTA) chemistry professor and Chief Scientific Officer of AeonClad Coatings. more
ETI Management
Tony Taylor President, Managing Director
		Tony Taylor serves as President and Managing Director for ETI portfolio company AeonClad Coatings. more
Breca Tracy, Ph.D. Assistant Managing Director
		Dr. Tracy currently serves on the management team for the ETI portfolio company, AeonClad Coatings as Assistant Managing Director, leading the clinical and biological division. more
William (Bill) Strieber Executive VP of Business Development
		William Strieber currently serves on the management team for the ETI portfolio company, AeonClad Coatings, as Executive VP of Business Development. more

AeonClad Coatings is an Emergent Technologies Inc. (ETI) portfolio company and ETI provides all management services and operations support.

About Emergent Technologies, Inc.

Headquartered in Austin, Texas, Emergent Technologies, Inc. (ETI) is a life sciences technology investment and management company which provides early stage funding and development for scientific discoveries originating at universities and research institutions. The Company creates value by transforming scientific breakthroughs into technology platforms with multiple applications. ETI's unique innovation process enables the Company to select promising scientific discoveries for development, maximize the value of intellectual property and manage both cost and risk associated with the commercial development of early stage technologies. ETI is dedicated to turning research into revenue and, in the process, introducing compelling solutions to meet important market needs. For more information, visit the company website www.etibio.com